# Treatment to Regress to Normoglycemia in Women with a Recent History of GDM

> **NCT04873050** · PHASE4 · RECRUITING · sponsor: **Woman's** · enrollment: 102 (estimated)

## Conditions studied

- Pre Diabetes
- Postpartum Disorder

## Interventions

- **DRUG:** Semaglutide Pen Injector [Ozempic]
- **DRUG:** Placebo semaglutide pen injector

## Key facts

- **NCT ID:** NCT04873050
- **Lead sponsor:** Woman's
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-01-13
- **Primary completion:** 2026-01-01
- **Final completion:** 2026-03-01
- **Target enrollment:** 102 (ESTIMATED)
- **Last updated:** 2025-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04873050

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04873050, "Treatment to Regress to Normoglycemia in Women with a Recent History of GDM". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04873050. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*